Continuing Education and Professional Development

The University of Tennessee Graduate School of Medicine Department of Anesthesiology presents the 5th Annual Targeted Pain Treatment® Conference on March 31, 2023 at the Hilton Knoxville Airport. This year’s conference theme will refocus on pain management through the lens of Awareness, Access, Application.

Course Overview

The use of opioids as the primary treatment for pain has contributed to the opioid crisis we now face in East Tennessee and the country.  This is because opioids do not target the underlying causes of pain and opioids have both physiologic and psychological effects that are the basis for opioid dependence, overdose and addition.  As awareness of the adverse effects of opioids has increased, many clinicians have restricted their use of opioids for chronic pain.  But unfortunately, without formal clinical education on or access to alternative, effective pain treatment options, this reduction in opioid use has also resulted in unwanted suffering and decreased function for patients who experience chronic pain.

Targeted Pain Treatment® the process of accurately diagnosing  the cause of pain, and then targeting the treatment to the cause, is an alternate, effective, and comprehensive approach to addressing the cause of pain and improving function and quality of life for patients.  

This conference is officially endorsed by the Tennessee Pain Society.

Requirements for continuing medical education credit regarding controlled substance prescribing

Targeted Pain Treatment® is a federally registered trademark owned by Dr. Stephanie Vanterpool.  Dr. Vanterpool developed and is responsible for the content contained in the TPT Toolkit.

Course Objectives

At the conclusion of this program, the participants should be able to:

• Review the scope and impact of the opioid crisis in East Tennessee
• Identify ways to apply the state and national guidelines that govern opioid prescribing and chronic pain treatment
• Identify and address provider and patient barriers to access for targeted pain treatment therapies for patients with acute and chronic pain
• Summarize the appropriate application of specific targeted pain treatment therapies that address the cause of chronic pain and how these treatments improve function and quality of life for patients.
  

Disclosures

There is no minimum threshold for financial disclosures; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies within the past 24 months. Individuals must disclose regardless of their view of the relevance of the relationship to the education. Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

The UT Graduate School of Medicine Office of Continuing Education and Professional Development along with the Co-Course Directors have taken appropriate steps to mitigate relationships prior to the individuals assuming their roles.  CME Planning Staff have no actual or potential conflicts of interest in relation to the presentations.

Education Credits

The University of Tennessee College of Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants, Nurse Practitioners and Nurses may use these credit hours toward certification renewal.  This credit is acceptable by the American Academy of Physician Assistants (AAPA), American Nurses Credentialing Association (ANCC) and the American Academy of Nurse Practitioners (AANP).

The University of Tennessee College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.